Trial site
Westpfalz-Klinikum GmbH
Kaiserslautern, 67655, GermanyNot linked to an institution yet
- 18running trials
- 6closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 2/32 trials
- Phase 21 trial
- Status
- Recruiting11 trials
- Active, not recruiting7 trials
- Completed6 trials
- Lead sponsor
- University of Heidelberg Medical Center3 trials
- German CLL Study Group2 trials
- Stichting Hemato-Oncologie voor Volwassenen Nederland2 trials
- University Of Cologne2 trials
- Boehringer Ingelheim1 trial
- and 14 more
Running trials
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Contact: Trial Registration Coordinator
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Source
Contact: Burghard Schumacher, MD (principal investigator)
Recruiting
Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
NCT05665608· Charite University, Berlin, Germany· Source
Contact: Gerhard Hindricks, Prof
Recruiting
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
NCT05820841· Phase 3· Universität des Saarlandes· Source
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884· Prof. Dr. Hartmut Goldschmidt· Source
Contact: Gerhard Held, Prof. Dr.
Recruiting
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· Phase 3· University of Ulm· Source
Active, not recruiting
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· Phase 3· German CLL Study Group· Source
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source
Active, not recruiting
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure
NCT04495088· Phase 3· Heidelberg University· Source
Active, not recruiting
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· Phase 3· University of Heidelberg Medical Center· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error